Zolgensma: Nine Steps Health Plans Can Take to Reduce Financial Exposure

By Martha Allen
Wed, Sep, 11, 2019

Zolgensma, the first single-dose gene therapy for SMA type 1, exposes health plans to significant financial risks because of its extraordinarily high price tag. The wholesale acquisition cost (WAC) for a one-time dose of Zolgensma is $2,125,000. The good news is that with advance planning, proactive review of existing contracts, and proactive discussions with your reinsurer, you can help reduce your plan’s potential financial liability associated with this unique and extremely costly specialty drug.

Privacy Policy